Phuturdex › Diseases › Prolymphocytic leukemia
Drugs in development · updated 30 October 2026
Prolymphocytic leukemia: drugs in development
As of 30 October 2026 there are 6 active clinical trials (recruiting or ongoing, phases I–III) on 15 drugs for prolymphocytic leukemia. 0 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | II | 3 | NCT06001385 |
| FludarabineFludara, FLUDARABIN | II | 3 | NCT06001385 |
| Mycophenolate MofetilMycophenolate, Cellcept | II | 3 | NCT06001385 |
| IbrutinibPCI 32765, Imbruvica® | II | 2 | NCT02007044 |
| AcalabrutinibACP-196, Calquence® | I–II | 1 | NCT02029443 |
| AllopurinolAloprim®, Lopurin® | II | 1 | NCT05805605 |
| BusulfanBusulphan, Busulfex® | II | 1 | NCT06001385 |
| CyclosporineCyclosporine A, Cyclosporin Capsules | II | 1 | NCT04195633 |
| FilgrastimRecombinant Human Granulocyte Colony-Stimulating Factor, Neupogen | II | 1 | NCT04195633 |
| MelphalanEvomela®, Hepzato® | II | 1 | NCT06001385 |
| MesnaUromitexan, Mesnex® | II | 1 | NCT06001385 |
| RituximabRuxience, Rituxan | II | 1 | NCT02007044 |
| SirolimusRapamycin, Scomara® | II | 1 | NCT05805605 |
| TacrolimusEnvarsus XR, Prograf® | II | 1 | NCT06001385 |
| TreosulfanGrafapex®, Trecondi® | II | 1 | NCT04195633 |
Sorted by most advanced phase and number of active trials.
All 15 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- T-cell prolymphocytic leukemia 8 drugs
- Chronic lymphocytic leukemia 137 drugs
- Non-Hodgkin lymphoma 269 drugs
- B-cell prolymphocytic leukemia 7 drugs
- Leukemia 153 drugs
- Burkitt lymphoma 113 drugs
- Diffuse large B-cell lymphoma 177 drugs
- Follicular lymphoma 144 drugs
- Lymphoma, B-Cell, Marginal Zone 86 drugs
- Mantle cell lymphoma 108 drugs
- Precursor lymphoblastic lymphoma/leukemia 163 drugs
- T-cell lymphoma 74 drugs
Broader categories
- Neoplasm 671 drugs
- Leukemia 153 drugs
- Hematologic Diseases 57 drugs
- Immune System Diseases 54 drugs
- Lymphoproliferative disorders 51 drugs
- Lymphatic system disease 20 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D015463 “Leukemia, Prolymphocytic”.